Mynvax
PrivateLast Round
Series A
Extension
May 24, 2024
Est. Valuation
$31M
Total Funding Raised
$6.8M
Company Overview
Mynvax is a biotechnology company that develops innovative drugs intended for use in influenza vaccines, focusing on treatments for flu and infectious diseases to support healthcare professionals in enhancing patient recovery.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Pharma Supply Chain
Business Model
B2G
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mynvax Comps
Public and private peers based on sector, stage, and business model.
Mynvax Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | May 24, 2024 | ||||
| Series A | Jul 19, 2021 | ||||
| Grant | Aug 1, 2020 | ||||
| Angel | Oct 18, 2018 |
Mynvax Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Inviga Healthcare Fund | Series A Extension |
| Kotak Investment Advisors | Series A |
| 1Crowd | Series A |
| Accel | Series A |
Mynvax Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Mynvax's valuation, stock price, and market status.
